Loading...
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma
PURPOSE: Consolidation/maintenance therapy induces deep remission in patients with multiple myeloma (MM); however, the most suitable regimen has been under investigation. The combination therapy with bortezomib, lenalidomide and dexamethasone (VRD) is a powerful regimen for relapsed/refractory as we...
Na minha lista:
| Udgivet i: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5083756/ https://ncbi.nlm.nih.gov/pubmed/27738809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3163-y |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|